Form 4: Oruka COO Sells Shares After Option Exercise

Oruka Therapeutics' Chief Operating Officer, Laura Sandler, exercised options and subsequently sold an equivalent number of shares under a pre-arranged trading plan.

Summary

• Laura Sandler, Chief Operating Officer of Oruka Therapeutics, Inc. (ORKA), reported transactions on March 2, 2026.
• Exercised employee warrants to acquire 5,000 shares of common stock at an exercise price of $7.8 per share.
• Sold 2,325 shares of common stock at a weighted average price of $33.2843 per share, with prices ranging from $32.66 to $33.64.
• Sold an additional 2,675 shares of common stock at a weighted average price of $33.8077 per share, with prices ranging from $33.66 to $34.33.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan established on September 19, 2025.
• Following these transactions, Sandler directly owns 237,584 shares of common stock and 89,996 derivative securities (employee warrants).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, reflecting a planned liquidity event for the COO rather than a direct signal about the company's immediate prospects. The significant profit from the option exercise is a positive for the insider.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned liquidity rather than opportunistic selling based on non-public information.
• The exercise price of $7.8 is significantly lower than the sale prices (weighted averages of $33.2843 and $33.8077), indicating a substantial realized gain for the insider.

Negatives

• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals about management's perception of future company performance. While these sales were pre-planned under a Rule 10b5-1 plan, the market often scrutinizes the timing and volume of such transactions within the biotech sector, where stock performance can be highly sensitive to news and insider activity.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling.

Next Steps

• Continued vesting of remaining employee warrants for Laura Sandler according to the established schedule.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Form 4, Insider Trading, Stock Sale, Option Exercise, Laura Sandler, 10b5-1 Plan, Chief Operating Officer